Prostate Cancer With OligometaSTatic Relapse: Combining Stereotactic Ablative Radiotherapy and Durvalumab (MEDI4736)

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

96

Participants

Timeline

Start Date

March 21, 2019

Primary Completion Date

December 27, 2023

Study Completion Date

December 27, 2027

Conditions
Node; ProstateBone MetastasesProstate Cancer Patients
Interventions
COMBINATION_PRODUCT

SBRT + Durvalumab

"Durvalumab, MEDI4736, is a immunotherapy,~SBRT (stereotactic body radiotherapy) is a procedure that uses high doses of radiation delivered to a precise target. By using special positioning and implanted markers in the body, radiologists are able to deliver a much higher dose of radiation to a cancer than traditional radiation therapy"

RADIATION

SBRT

SBRT (stereotactic body radiotherapy) is a procedure that uses high doses of radiation delivered to a precise target. By using special positioning and implanted markers in the body, radiologists are able to deliver a much higher dose of radiation to a cancer than traditional radiation therapy

Trial Locations (9)

21079

Centre Georges François Leclerc, Dijon

29200

CHRU de Brest, Brest

33076

Institut Bergonie, Bordeaux

34298

Institut de Cancérologie de Montpellier, Montpellier

44805

ICO, Saint-Herblain

56100

Chbs Lorient, Lorient

59020

Centre Oscar Lambret, Lille

69310

Hospices Civils de Lyon, Pierre-Bénite

69373

Centre Léon Bérard, Lyon

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

lead

Institut Cancerologie de l'Ouest

OTHER